NCT02870582 2022-11-29
Donafenib for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Completed
Clinical Trials
3 trialsNCT02870569 2019-03-01
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Completed
NCT02489916 2016-01-05
Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Completed